Go to content
UR Home

The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders—a double-blind, randomized, placebo-controlled proof-of-concept study

URN to cite this document:
DOI to cite this document:
Brunner, Lisa-Marie ; Riebel, Marco ; Wein, Simon ; Koller, Michael ; Zeman, Florian ; Huppertz, Gunnar ; Emmer, Tanja ; Eberhardt, Yvonne ; Schwarzbach, Jens ; Rupprecht, Rainer ; Nothdurfter, Caroline
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 29 May 2024 11:01


Background Recent developments suggest that neurosteroids may achieve rapid antidepressant effects. As such, neurosteroidogenesis mediated by the translocator protein 18 kDa (TSPO) might constitute a promising option for the treatment of depression. Therefore, the current clinical trial aims to get the first evidence of whether TPSO ligands promote rapid antidepressant effects. Furthermore, we ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons